CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2023. The put-call ratio across all filers is 1.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,000,500 | -19.7% | 183,257 | +17.0% | 0.00% | -50.0% |
| Q2 2023 | $4,980,158 | +14.3% | 156,658 | -12.3% | 0.00% | +100.0% |
| Q1 2023 | $4,355,445 | -16.4% | 178,575 | +8.1% | 0.00% | -50.0% |
| Q4 2022 | $5,208,453 | +866.3% | 165,138 | +765.5% | 0.00% | – |
| Q3 2022 | $539,000 | -61.1% | 19,081 | -63.6% | 0.00% | -100.0% |
| Q2 2022 | $1,387,000 | +7.4% | 52,424 | +42.1% | 0.00% | – |
| Q1 2022 | $1,291,000 | -81.2% | 36,895 | -82.5% | 0.00% | -100.0% |
| Q4 2021 | $6,853,000 | +2720.2% | 211,382 | +2471.6% | 0.00% | – |
| Q3 2021 | $243,000 | +45.5% | 8,220 | +26.5% | 0.00% | – |
| Q2 2021 | $167,000 | +45.2% | 6,500 | -22.6% | 0.00% | – |
| Q1 2021 | $115,000 | -48.2% | 8,403 | -37.2% | 0.00% | – |
| Q4 2020 | $222,000 | – | 13,372 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,713,470,000 | 41.39% |
| Perceptive Advisors | 6,511,727 | $184,021,000 | 5.34% |
| Finepoint Capital LP | 536,901 | $15,173,000 | 4.99% |
| Artal Group S.A. | 2,000,000 | $56,520,000 | 2.41% |
| Rock Springs Capital Management LP | 2,499,148 | $70,626,000 | 1.82% |
| Ikarian Capital, LLC | 178,100 | $5,033,000 | 1.00% |
| Hood River Capital Management LLC | 896,572 | $25,337,000 | 0.97% |
| Frazier Life Sciences Management, L.P. | 393,000 | $11,106,000 | 0.86% |
| HighVista Strategies LLC | 23,611 | $667,000 | 0.38% |
| FEDERATED HERMES, INC. | 3,313,333 | $93,635,000 | 0.27% |